These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32585491)

  • 21. Tau pathology mediated the plasma biomarkers and cognitive function in patients with mild cognitive impairment.
    Zhao L; Qiu Q; Zhang S; Yan F; Li X
    Exp Gerontol; 2024 Oct; 195():112535. PubMed ID: 39128687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study.
    Götze K; Vrillon A; Dumurgier J; Indart S; Sanchez-Ortiz M; Slimi H; Raynaud-Simon A; Cognat E; Martinet M; Zetterberg H; Blennow K; Hourrègue C; Bouaziz-Amar E; Paquet C; Lilamand M
    Alzheimers Res Ther; 2024 Oct; 16(1):231. PubMed ID: 39427171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study.
    Dong Y; Hou T; Li Y; Liu R; Cong L; Liu K; Liu C; Han X; Ren Y; Tang S; Winblad B; Blennow K; Wang Y; Du Y; Qiu C
    J Alzheimers Dis; 2023; 96(2):845-858. PubMed ID: 37899059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
    Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
    ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF neurofilament light may predict progression from amnestic mild cognitive impairment to Alzheimer's disease dementia.
    Lim B; Grøntvedt GR; Bathala P; Kale SS; Campbell CT; Stengelin M; Sando SB; Prassas I; Diamandis EP; Bråthen G
    Neurobiol Aging; 2021 Nov; 107():78-85. PubMed ID: 34403936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer's disease.
    Knudtzon SL; Nordengen K; Grøntvedt GR; Jarholm J; Eliassen IV; Selnes P; Pålhaugen L; Espenes J; Gísladóttir B; Waterloo K; Fladby T; Kirsebom BE
    Neurobiol Aging; 2024 Sep; 141():74-84. PubMed ID: 38838442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma tau and neurofilament light chain as biomarkers of Alzheimer's disease and their relation to cognitive functions.
    Abed SS; Hamdan FB; Hussein MM; Al-Mayah QS
    J Med Life; 2023 Feb; 16(2):284-289. PubMed ID: 36937471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
    Rauchmann BS; Schneider-Axmann T; Perneczky R;
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years.
    Darmanthé N; Tabatabaei-Jafari H; Cherbuin N;
    J Alzheimers Dis; 2021; 82(3):951-964. PubMed ID: 34120902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology.
    Liu HC; Lin WC; Chiu MJ; Lu CH; Lin CY; Yang SY
    PLoS One; 2020; 15(6):e0234519. PubMed ID: 32530970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    Vrillon A; Ashton NJ; Karikari TK; Götze K; Cognat E; Dumurgier J; Lilamand M; Zetterberg H; Blennow K; Paquet C
    J Neurol; 2024 Mar; 271(3):1297-1310. PubMed ID: 37950758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.
    Marks JD; Syrjanen JA; Graff-Radford J; Petersen RC; Machulda MM; Campbell MR; Algeciras-Schimnich A; Lowe V; Knopman DS; Jack CR; Vemuri P; Mielke MM;
    Alzheimers Res Ther; 2021 Dec; 13(1):199. PubMed ID: 34906229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study.
    Rajan KB; Aggarwal NT; McAninch EA; Weuve J; Barnes LL; Wilson RS; DeCarli C; Evans DA
    Ann Neurol; 2020 Dec; 88(6):1065-1076. PubMed ID: 32799383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.
    Alcolea D; Delaby C; Muñoz L; Torres S; Estellés T; Zhu N; Barroeta I; Carmona-Iragui M; Illán-Gala I; Santos-Santos MÁ; Altuna M; Sala I; Sánchez-Saudinós MB; Videla L; Valldeneu S; Subirana A; Pegueroles J; Hirtz C; Vialaret J; Lehmann S; Karikari TK; Ashton NJ; Blennow K; Zetterberg H; Belbin O; Blesa R; Clarimón J; Fortea J; Lleó A
    J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1206-1214. PubMed ID: 34103344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.